Program Highlights

Tuesday, 18 October

16:00-17:00
Opening Session
supported by BlueBird Bio


Opening Remarks

Nathalie Cartier, President, ESGCT

Luigi Naldini, ESGCT Local Organizing Committee President

Nancy Witty, CEO, ISSCR

OPENING KEYNOTE
Hans Clevers, Hubrecht Institute, Netherlands

17:00-19:00
PLENARY SESSION 1: Neural Diseases       
supported by RegenX

Fred Gage, Salk Institute for Biological Studies, USA

Masayo Takahashi, CDB, RIKEN, Japan

Paul Tesar, Case Western Reserve University, USA

Malin Parmar, Lund University, Sweden

19:00-20:00
Welcome Reception

Wednesday, 19 October

8:30-10:30
PLENARY SESSION 2: Hematopoietic Stem Cells
supported by Genethon

John Dick, University Health Network, Canada

Leonard Zon, Boston Children's Hospital, USA

Luigi Naldini,  San Raffaele Telethon Institute for Gene Therapy_TIGET, Italy

Marina Cavazzana, Hopital Necker-Enfants Malades, France

11:00-12:30
Parallel Session 2

Parallel 2a: Imaging Stem Cell Dynamics

Valentina Greco, Yale Medical School, USA

Timm Schroeder, Swiss Federal Institute of Technology (ETH) Zürich, Switzerland

Parallel 2b: Eye Stem Cell and Gene Therapy supported by MeiraGtx

Graziella Pellegrini, University of Modena and Reggio Emilia, Italy

Deniz Dalkara, Institut de la Vision in Paris, France

Parallel 2c: Central Nervous System Gene Therapy 

Alessandra Biffi, Boston Children's Hospital, USA

Shin-ichi Muramatsu, Jichi Medical University, Japan

14:00-16:00
PLENARY SESSION 3: Skeletal and cardiac muscle stem cells
supported by FinVector
In memoriam Paolo Bianco

Christine Mummery, Leiden University Medical Center, Netherlands

Mauro Giacca, International Centre for Genetic Engineering and Biotechnology, Italy

Michael Laflamme, University of Washington, USA

Luis Garcia, UFR Des Sciences de la Santé Simone Veil, France

16:30-18:30
Parallel Session 3

Parallel 3a: Organoids and high throughput platforms

Sergiu Pasca, Stanford University, USA

David Tuveson, Cold Spriing Harbor Laboratory, USA

Parallel 3b: Stem cell based neural disease modelling

Giuseppe Testa, European Institute of Oncology, Italy

Angel Raya, Center of Regenerative Medicine in Barcelona (CMR [B]), Spain

Parallel 3c: Cardiovascular Gene and Cell Therapy

Seppo Ylä-Herttuala, University of Eastern Finland, Finland

Andrew Baker, University of Glasgow, UK

Parallel 3d: Immunology/ Cancer immuno gene therapy I

David Klatzman, Pierre and Marie Curie Medical School, France

Wasseem Qasim, Institute of Child Health, UCL, UK

18:30-20:30
Poster Session I

Thursday, 20 OCTOBER

8:00-10:00
Plenary Session 4: Cancer Immuno – Gene Therapy
supported by Oxford Biomedica

Gianpietro Dotti, University of North Carolina, USA

Stanley Riddell, Universityof Washington, USA

Carl June, University Pennsylvania School of Medicine, USA

Chiara Bonini, San Raffaele Scientific Institute, Italy

10:30-12:30
Parallel Session 4

Parallel 4a: Hematopoietic Stem Cells and Homeostasis

Michael Milsom, Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM), Heidelberg, Germany

Emmanuelle Passegue, University of California San Francisco, USA

Parallel 4b: MSC Gene and Cell Therapy

Wilfried Daelemans, TeGenix, Belgium

Willem Fibbe, Leiden University Medical Center, Netherlands

Parallel 4c: In vivo Gene Therapy

supported by Adverum

Federico Mingozzi, University Pierre and Marie Curie and Genethon, France

Katherine High, Spark Therapeutics, USA

14:00-16:00
Parallel Session 5

Parallel 5a: Cancer Stem Cells

Michael Clarke, Stanford University, USA

Dominique Bonnet, The Francis Crick Institute, UK

Inder Verma, The Salk Institute, USA

Parallel 5b: Ex Vivo HSC Based Gene and Cell Therapy

Don Kohn,University of California, Los Angeles,USA

Cynthia Dunbar, National Institutes of Health, USA

Parallel 5c: DNA based gene transfer and integration studies

James Wilson, Perelman School of Medicine, USA

16:30-18:30
Plenary Session 5: New technologies: targeted genome and epigenome editing new vector design, organoids
supported by Editas

Angelo Lombardo, SR-Tiget, Italy

Feng Zhang, Broad Institute MIT, USA

Melissa Little, Murdoch Children's Research Institute, University of Melbourne, Australia

Pierre Vanderhaegen, Universite Libre de Bruxelles, Belgium

18:40-20:00
Poster Session 2

Friday, 21 OCTOBER

9:00-10:30
Parallel Session 6

Parallel 6a: RNA Based Gene Transfer and Integration studies

Luca Biasco, San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), Italy

Christof von Kalle, Cincinnati Children's Hospital Medical Center, USA

Parallel 6b: Genome Editing and Gene Correction

Toni Cathomen, University Medical Center Freiburg, Germany

Charles Gersbach,, Duke University, USA

Parallel 6c: Cancer Gene Therapy

Ramon Alemany, Catalan Institute of Oncology, Spain

Yasutomo Nasu, Okayama Medical School, Japan

Parallel 6d: Immunology and Allergy

Ron Crystal, Weill Cornell Medical College, USA

Maria Grazia Roncarolo, Stanford University, USA

10:30-11:30
ESGCT Plenary Session 6: Gene Therapy on the market
supported by GSK

Jonathan Appleby, GSK, UK

Alessandro Aiuti,, Ospedale San Raffaele – Milano, Italy

Sol Ruiz, European Medicines Agency, Spain

Julie Venners Christensen, GSK, UK

12:00-13:30
ESGT Plenary session 7:In Vivo Gene Therapy
supported by Biogen

Alberto Auricchio, Fondazione Telethon - TIGEM, Italy

Mark Kay, Stanford University, USA

14:30-16:00
Parallel Session 7

Parallel 7a: Immunology/ Cancer Immuno Gene Therapy I

Dirk Busch, Technische Universität München (TUM), Germany

Bernhard Gentner, San Raffaele Telethon Institute for Gene Therapy, Italy

Parallel 7b: Gene Silencing: From small non-coding RNAs to epigenetic editing and gene disruption

Michael Holmes, Sangamo, USA

Frank Slack, Yale University, USA

Parallel 7c: Manufacturing of Cell and Gene Therapy Products supported by Molmed

Ian Johnston, Miltenyi Biotec GmbH, Germany

Paolo Rizzardi, MolMed SpA, Italy

Parallel 7d: CNS Gene Therapy supported by AvexisBio

Nathalie Cartier, Université Paris Descartes, INSERM U745, France

Jerry Mendell, Nationwide Children's Hospital, USA

16:00-17:30
ESGCT PRESIDENTIAL SYMPOSIUM

George Q. Daley, Boston Children's Hospital, USA

Amit Nathwani, University College London, UK (Outstanding Achievement Award)

TBA (Young Investigator Award)

17:30-18:30
Germline Editing Debate

Annelien Bredenoord, UMC Utrecht, Netherlands

Nathalie Cartier, Université Paris Descartes, INSERM U745, France

George Q. Daley, Boston Children's Hospital, USA

Luigi Naldini, San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), Italy

Giuseppe Testa, European Institute of Oncology, Italy

Feng Zhang, Broad Institute of MIT and Harvard, USA

18:30-19:00
Closing Drinks

Richard Young is a Professor at the Whitehead Institute and MIT. Dr. Young studies gene regulation in health and disease. His honors include Membership in the National Academy of Sciences and Scientific American has recognized him as one of the top 50 leaders in science, technology and business.
Shinya Yamanaka is a professor and the director of the Center for iPS Cell Research and Application (CiRA) at Kyoto University and a senior investigator at the Gladstone Institute of Cardiovascular Disease in San Francisco. Born in Osaka in 1962, he received a M.D. from Kobe University and a Ph.D. from Osaka City University. After working as a postdoctoral fellow at Gladstone between 1993 and 1996, he took up an assistant professorship at OCU in 1996 and an associate professorship at the Nara Institute of Science and Technology in 1999. Moving to Kyoto University in 2004, he reported in 2006 that his team succeeded in generating Shinya Yamanaka is a professor and the director of the Center for iPS Cell Research and Application (CiRA) at Kyoto University and a senior investigator at the Gladstone Institute of Cardiovascular Disease in San Francisco. Born in Osaka in 1962, he received a M.D. from Kobe University and a Ph.D. from Osaka City University. After working as a postdoctoral fellow at Gladstone between 1993 and 1996, he took up an assistant professorship at OCU in 1996 and an associate professorship at the Nara Institute of Science and Technology in 1999. Moving to Kyoto University in 2004, he reported in 2006 that his team succeeded in generating induced pluripotent stem (iPS) cells. For this discovery, Yamanaka received the 2012 Novel Prize in Physiology or Medicine.
Noriyuki Tsumaki is currently Professor at the Center for iPS Cell Research and Application (CiRA), Kyoto University, Japan, where he researches cartilage biology and regeneration of cartilage using cell reprogramming technologies. He earned his M.D. from Osaka University, Japan in 1989. There he completed his Ph.D. in 1996.
Masayo Takahashi M.D., Ph.D. Project leader, Laboratory for Retinal Regeneration Research at RIKEN. As a retina specialist, she aims to better understand macular diseases and retinal hereditary diseases with the ultimate goal of developing novel retinal regeneration therapies.
Jun Takahashi is a professor of Center for iPS Cell Research and Application (CiRA) at Kyoto University, Kyoto, Japan. He is a neurosurgeon at Kyoto University Hospital, and also doing research works to develop stem cell therapy using iPS cells for Parkinson’s disease.
Dr Robins bio to come
Kathrin Plath, Ph.D., is a Professor in the Department of Biological Chemistry at the David Geffen School of Medicine and the Broad Stem Cell Center at UCLA. The Plath lab focuses on the epigenetic mechanisms that maintain pluripotency and on dissecting the epigenetic changes that are required for differentiation and reprogramming processes.
Dr. Ryuichi Nishinakamura is a professor in the Department of Kidney Development at the Institute of Molecular Embryology and Genetics, Kumamoto University, Japan. His research focuses on the molecular basis of kidney development, which has led to the creation of three-dimensional kidney tissues from pluripotent stem cells.
After obtaining MD and PhD in Japan, Hiro Nakauchi went to Stanford University for post-doc and isolated CD8 genes. After coming back to Japan, he started working on hematopoietic stem cells in his laboratory in RIKEN. In 1994, he became Professor of Immunology in the University of Tsukuba where he determined the phenotype of mouse hematopoietic stem cells and established an in vivo clonal analysis system. In 2002, he became a Professor of Stem Cell Therapy in the Institute of Medical Science at the University of Tokyo (IMSUT). In 2008, he was appointed as a director of newly established Center for Stem Cell Biology and Regenerative Medicine in IMSUT. In January 2014, he is starting a new lab at the Institute of Stem Cell Biology and Regenerative Medicine, Stanford University. Goals of his work are to clarify the mechanism of stem cell self-renewal and to contribute to the cell/gene therapy and regenerative medicine.
Dr Murry bio to come .
Gordon Keller, PhD is a Senior Scientist at the University Health Network’s (UHN) Princess Margaret Cancer Centre, Professor at the University of Toronto and Director of UHN’s McEwen Centre for Regenerative Medicine. His studies are focused on deciphering the cues that direct pluripotent stem cells to make different cell types.
Dr. Jaenisch received his M.D. degree from the University of Munich in 1967. After postdoctoral research at Princeton and the Fox Chase Cancer Center, he first joined the faculty at the Salk Institute and later became Head of the Department of Tumor Virology of the Heinrich-Pette Institute in Hamburg. In 1984 he was recruited as a Founding Member of the Whitehead Institute for Biomedical Research and Professor of Biology at the Massachusetts Institute of Technology. The overall focus of Dr. Jaenisch’s research is on epigenetics, reprogramming and stem cell biology.
Dr. Eto was originally clinical physician of cardiovascular medicine. After he started cell biology research at The Scripps Research Institute in 1999, he changed the focus from thrombosis to platelet biology and biogenesis. In 2003, Dr. Eto became an Assistant Professor at Institute of Medical Science, The University of Tokyo. In 2009, he was appointed Associate Professor at The University of Tokyo. He took his current position as a professor at CiRA, Kyoto University in 2011. Dr. Eto earned an MD from Yamanashi University in 1990 and a PhD in 1996. From 1999 to 2003, he was a postdoctoral fellow at The Scripps Research Institute, La Jolla, CA.
Andrew Elefanty is group leader of the Blood Cell Development and Disease laboratory at the Murdoch Childrens Research Institute in Melbourne, Australia. His core interest lies in the regulation of human pluripotent stem cell differentiation to mesoderm and endoderm. He has extensive experience in the genetic modification of PSCs, generating lines into which reporter genes have been inserted by homologous recombination in gene loci that are expressed in specific lineages.
Dr. Dunbar is the Head of the Molecular Hematopoiesis Section within the National Heart, Lung, and Blood Institute at the NIH. She is a physician-scientist focusing on hematopoiesis and on the development of novel cell and gene therapies utilizing the non-human primate model.
Luc Douay, MD, PhD is senior Professor of hematology at the University Pierre et Marie Curie, director of the hematology lab of Saint Antoine Hospital, director of Inserm research Unit and scientific director of Paris French Blood Bank (EFS), France. He is a world pioneer and leader in the concept of Red blood Cells generated in vitro from stem cells for transfusion purpose.
George Q. Daley is the Samuel Lux IV Professor of Hematology/Oncology and the Director of the Stem Cell Transplantation Program at Children’s Hospital Boston, Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School, and an investigator of the Howard Hughes Medical Institute. His research entails understanding pathways that influence both stem cell reprogramming and cancer.
Gordon Keller, PhD is a Senior Scientist at the University Health Network’s (UHN) Princess Margaret Cancer Centre, Professor at the University of Toronto and Director of UHN’s McEwen Centre for Regenerative Medicine. His studies are focused on deciphering the cues that direct pluripotent stem cells to make different cell types.